Nova In Silico is attending ACoP 2026 with eight posters, one oral presentation, and one hands-on tutorial.
Published
Signal category
Presence & Recognition
Quote
“ACoP 2026 is coming soon, and we’ll be there with eight posters, one oral presentation and one hands-on tutorial.”
— Nova In Silico team
Company
Nova In Silico
Every clinical trial should be simulated first
- Industry
- Software Development
- Location
- Lyon, FR
- Company size
- 65 employees
Nova provides its jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers and not-for-profit organizations. Jinkō® unlocks the potential of modeling & simulation to de-risk and accelerate the R&D of new therapies for the benefit of patients: identify best responders, optimise the drug's regimen, generate synthetic control arms, explore research outcomes that might not be feasible with conventional trials. Predict trial outcomes before advancing to real-world clinical trials and ultimately design studies that are more likely to succeed with Jinkō®.
Founded 2010